Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From ObsEva SA
After a brief lull in US initial public offerings, PainReform and three special purpose acquisition companies kicked off September’s IPOs. Also, Immunovant offering grossed $173.9m, Carlyle Group bought 5% stake in China’s Salubris and Erasca increased its series B to $236m.
Positive data from a second Phase III trial will support regulatory filings for linzagolix in the US and Europe, but the GnRH agonist is behind two rival drugs: AbbVie's elagolix and Myovant's relugolix.
BeiGene licenses antibody therapeutics for Castleman’s disease and high-risk neuroblastoma.
Shares plummet as ObsEva announces it is discontinuing its IVF program for nolasiban after disappointing Phase III data from a European confirmatory study.
- Specialty Pharmaceuticals